Christophe Van Vaeck works within Gimv’s Health & Care platform since 9 years, where he gained broad experience ranging from early biotech, diagnostic and medtech companies up to mature private clinics. After the recent successful exit of Multiplicom, he is currently still a board member at Almaviva, Spineart and Agrosavfe. Before joining Gimv, Christophe was a financial analyst Life Sciences at Bank Degroof and KBC Securities, where he guided the Euronext IPOs of Galapagos, deVGen, Thrombogenics and Ablynx. Christophe earned his PhD in Molecular Cell Biology at K.U. Leuven, Belgium, in 2000.